Dr. Mikhail Kosiborod with Saint Luke’s Mid-America Heart Institute is leading a clinical trial investing the use of a diabetic drug called dapagliflozin. Apparently, a new study commenced to look the drug as a means of protecting vital organs from damage caused by COVID-19.
With the study’s launch just last week, sponsor Saint Luke’s Health System along with collaborator (and drug maker) AstraZeneca set up this international, multicenter, parallel-group, randomized, double-blind, placebo controlled clinical trial for hospitalized adult patients with COVID-19 in the United States and other countries with high prevalence of COVID-19. The study team now evaluates the effect of 10mg of dapagliflozin versus placebo, given once daily for 30 days in addition to the local standard of care therapy with the goal of reducing disease progression, complication and all-cause mortality.
Seeking a total of 900 participants, the study will include sites around the world including places such as Australia as CRO George Clinical also participates to help manage the study. Some of the participants are already enrolled at the Kansas City sponsor. These patients are already hospital...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).